Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient

Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient

Respiratory syncytial virus (RSV) is an important community-acquired pathogen that can cause significant morbidity and mortality in patients who have compromised pulmonary function, are elderly, or are immunosuppressed. This paper describes a 70-year-old man with a remote history of heart transplant...

Full description

Bibliographic Details
Main Authors:	J. L. Grodin, K. S. Wu, E. E. Kitchell, J. Le, J. D. Mishkin, M. H. Drazner, D. W. Markham
Format:	Article
Language:	English
Published:	Hindawi Limited 2012-01-01
Series:	Case Reports in Cardiology
Online Access:	http://dx.doi.org/10.1155/2012/723407

Similar Items

Respiratory Syncytial Virus and Palivizumab: Where are We in 2014?
by: Joan Robinson
Published: (2014-01-01)

Mechanism of human respiratory syncytial virus (hRSV) resistance to palivizumab
by: Welsh, Sarah Helen
Published: (2009)

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
by: Jennifer Claydon, et al.
Published: (2017-01-01)

THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS
by: A. V. Rudakova, et al.
Published: (2012-07-01)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
by: Asunci&oacute;n Mej&iacute;as, et al.
Published: (2008-09-01)

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation
by: D Wang, et al.
Published: (2008-12-01)

PALIVIZUMAB: NEW CAPABILITIES TO PREVENT SEVERE FORMS OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN
by: T.V. Kulichenko
Published: (2010-07-01)

PALIVIZUMAB: NEW CAPABILITIES TO PREVENT SEVERE FORMS OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN
by: T.V. Kulichenko
Published: (2010-07-01)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
by: Abushahin A, et al.
Published: (2018-01-01)

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
by: Agata Antepowicz, et al.
Published: (2021-08-01)

Detection of ON1 and novel genotypes of human respiratory syncytial virus and emergence of palivizumab resistance in Lebanon.
by: Hadi Abou-El-Hassan, et al.
Published: (2019-01-01)

The effect of palivizumab prophylaxis on respiratory syncytial virus-associated hospitalizations in infants with congenital diaphragmatic hernia
by: Pei-Lan Shao
Published: (2018-04-01)

Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
by: Bernhard Resch, et al.
Published: (2017-04-01)

The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut
by: Anna Banerji, et al.
Published: (2014-01-01)

GUIDELINES FOR THE USE OF SPECIFIC MONOCLONAL ANTIBODIES (PALIVIZUMAB) FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN SLOVENIA
by: Marko Pokorn, et al.
Published: (2002-10-01)

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention.
by: Jinghan Jenny Chen, et al.
Published: (2015-01-01)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
by: Gary M. Ginsberg, et al.
Published: (2018-12-01)

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.

A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.
by: Hsin Chi, et al.
Published: (2014-01-01)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
by: M. Sanchez-Luna, et al.
Published: (2017-10-01)

Detection of respiratory syncytial virus & Mycoplasma pneumoniae in paediatric lower respiratory tract infections
by: Sanchit Kumar, et al.
Published: (2019-01-01)

Effect of SynagisⓇ (palivizumab) prophylaxis on readmission due to respiratory syncytial virus in very low birth weight infants
by: Soo Kyoung Park, et al.
Published: (2010-03-01)

Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use
by: Silva Camila de A, et al.
Published: (2012-05-01)

Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
by: M. Elhalik, et al.
Published: (2019-01-01)

Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease
by: Mohammed Hassan A. Mohammed, et al.
Published: (2021-02-01)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
by: Roseane Porfírio de Souza, et al.
Published: (2019-08-01)

Role of Respiratory Syncytial Virus in Pediatric Pneumonia
by: Sonia Bianchini, et al.
Published: (2020-12-01)

Respiratory infections in children up to two years of age on prophylaxis with palivizumab
by: Ana Isabel M. P. Monteiro, et al.
Published: (2014-06-01)

A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation
by: Turti Tatyana V, et al.
Published: (2012-09-01)

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
by: Griffin M Pamela, et al.
Published: (2010-06-01)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
by: Rodica Gilca, et al.
Published: (2020-12-01)

Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection
by: Masaaki Mori, et al.
Published: (2021-03-01)

Influence of Pneumococcal Vaccines and Respiratory Syncytial Virus on Alveolar Pneumonia, Israel
by: Daniel M. Weinberger, et al.
Published: (2013-07-01)

Lower Respiratory Tract Infection in a Renal Transplant Recipient: Do not Forget Metapneumovirus
by: N. Noel, et al.
Published: (2012-01-01)

Streptococcus pneumoniae Enhances Human Respiratory Syncytial Virus Infection In Vitro and In Vivo.
by: D Tien Nguyen, et al.
Published: (2015-01-01)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
by: Ravasio Roberto, et al.
Published: (2009-02-01)

Respiratory Syncytial Virus Lower Respiratory Tract Infections in Premature Infants and Infants with Bronchopulmonary Dysplasia
by: D. Yu. Ovsyannikov, et al.
Published: (2015-10-01)

The burden of hospitalized lower respiratory tract infection due to respiratory syncytial virus in rural Thailand.
by: Alicia M Fry, et al.
Published: (2010-01-01)

Cannot write session to /tmp/vufind_sessions/sess_qmlvri65vksmvg90299t26nbks